Company News

Share this article:
Bristol, Tennessee-based Graceway Pharmaceuticals announced an agreement with Pfizer to acquire worldwide commercial rights for three investigational dermatological molecules. Two of the molecules will potentially treat oily skin and acne; both are in phase 2 of development. The third molecule, an ALK-5 inhibitor, is in pre-clinical development and would reduce surgical and traumatic scar formation. Financial terms of the deal were not disclosed.

Euro RSCG acquired Medicom Group, a UK-based medical communications agency. Medicom employs roughly 20, according to the company's LinkedIn profile.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions